Compare RMBI & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMBI | NBP |
|---|---|---|
| Founded | 1887 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.0M | 225.5M |
| IPO Year | 2019 | N/A |
| Metric | RMBI | NBP |
|---|---|---|
| Price | $15.56 | $1.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 71.9K | ★ 695.4K |
| Earning Date | 04-23-2026 | 04-07-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | ★ 27.17 | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $54.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.77 | $1.46 |
| 52 Week High | $16.59 | $5.19 |
| Indicator | RMBI | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 56.59 | 46.17 |
| Support Level | $14.10 | $1.67 |
| Resistance Level | $16.31 | $1.95 |
| Average True Range (ATR) | 0.60 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 60.00 | 17.14 |
Richmond Mutual Bancorp Inc is a bank holding company. Along with its subsidiary, it is mainly engaged in attracting deposits from the general public, as well as brokered deposits, and investing those funds in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one- to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. It also obtains funds by utilizing Federal Home Loan Bank (FHLB) advances. These funds are generally invested in investment securities, including mortgage-backed and mortgage-related securities and agency and municipal bonds. The Group's primary market area includes Wayne and Shelby counties in Indiana and Shelby, Miami, and Franklin counties in Ohio.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.